Literature DB >> 18073393

Respiratory infections: do we ever recover?

John Goulding1, Robert Snelgrove, José Saldana, Arnaud Didierlaurent, Mary Cavanagh, Emily Gwyer, Jeremy Wales, Erika L Wissinger, Tracy Hussell.   

Abstract

Although the outcome of respiratory infection alters with age, nutritional status, and immunologic competence, there is a growing body of evidence that we all develop a unique but subtle inflammatory profile. This uniqueness is determined by the sequence of infections or antigenic insults encountered that permanently mold our lungs through experience. This experience and learning process forms the basis of immunologic memory that is attributed to the acquired immune system. But what happens if the pathogen is not homologous to any preceding it? In the absence of cross-specific acquired immunity, one would expect a response similar to that of a subject who had never been infected with anything before. It is now clear that this is not the case. Prior inflammation in the respiratory tract alters immunity and pathology to subsequent infections even when they are antigenically distinct. Furthermore, the influence of the first infection is long lasting, not dependent on the presence of T and B cells, and effective against disparate pathogen combinations. We have used the term "innate imprinting" to explain this phenomenon, although innate education may be a closer description. This educational process, by sequential waves of infection, may be beneficial, as shown for successive viral infections, or significantly worse, as illustrated by the increased susceptibly to life-threatening bacterial pneumonia in patients infected with seasonal and pandemic influenza. We now examine what these long-term changes involve, the likely cell populations affected, and what this means to those studying inflammatory disorders in the lung.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18073393      PMCID: PMC2647650          DOI: 10.1513/pats.200706-066TH

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  106 in total

1.  Induction of a homeostatic circuit in lung tissue by microbial compounds.

Authors:  Kenji Takabayshi; Maripat Corr; Tomoko Hayashi; Vanessa Redecke; Lucinda Beck; Donald Guiney; Dean Sheppard; Eyal Raz
Journal:  Immunity       Date:  2006-04       Impact factor: 31.745

2.  IFN-induced attrition of CD8 T cells in the presence or absence of cognate antigen during the early stages of viral infections.

Authors:  Kapil Bahl; Sung-Kwon Kim; Claudia Calcagno; Dario Ghersi; Roberto Puzone; Franco Celada; Liisa K Selin; Raymond M Welsh
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

3.  Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia.

Authors:  Koenraad F van der Sluijs; Monique Nijhuis; Johannes H M Levels; Sandrine Florquin; Andrew L Mellor; Henk M Jansen; Tom van der Poll; René Lutter
Journal:  J Infect Dis       Date:  2005-12-14       Impact factor: 5.226

4.  CD11b regulates recruitment of alveolar macrophages but not pulmonary dendritic cells after pneumococcal challenge.

Authors:  Alun C Kirby; John G Raynes; Paul M Kaye
Journal:  J Infect Dis       Date:  2005-12-01       Impact factor: 5.226

5.  Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells.

Authors:  Dayna J Groskreutz; Martha M Monick; Linda S Powers; Timur O Yarovinsky; Dwight C Look; Gary W Hunninghake
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

6.  Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease.

Authors:  Ann R Falsey; Maria A Formica; Patricia A Hennessey; Mary M Criddle; Wayne M Sullender; Edward E Walsh
Journal:  Am J Respir Crit Care Med       Date:  2005-12-30       Impact factor: 21.405

Review 7.  Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not.

Authors:  Graham A W Rook; Keertan Dheda; Alimuddin Zumla
Journal:  Tuberculosis (Edinb)       Date:  2006-02-28       Impact factor: 3.131

8.  Colonic bacterial infection abrogates eosinophilic pulmonary disease.

Authors:  Andrew E Williams; Lorna Edwards; Tracy Hussell
Journal:  J Infect Dis       Date:  2005-12-14       Impact factor: 5.226

Review 9.  Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity.

Authors:  Liisa K Selin; Michael A Brehm; Yuri N Naumov; Markus Cornberg; Sung-Kwon Kim; Shalyn C Clute; Raymond M Welsh
Journal:  Immunol Rev       Date:  2006-06       Impact factor: 12.988

10.  Amelioration of influenza-induced pathology in mice by coinfection with Trichinella spiralis.

Authors:  Rebecca C Furze; Tracy Hussell; Murray E Selkirk
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

View more
  27 in total

Review 1.  Do multiple concurrent infections in African children cause irreversible immunological damage?

Authors:  Sarah J Glennie; Moffat Nyirenda; Neil A Williams; Robert S Heyderman
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

2.  Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice.

Authors:  Anupa Kudva; Erich V Scheller; Keven M Robinson; Chris R Crowe; Sun Mi Choi; Samantha R Slight; Shabaana A Khader; Patricia J Dubin; Richard I Enelow; Jay K Kolls; John F Alcorn
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

Review 3.  Does tissue imprinting restrict macrophage plasticity?

Authors:  Martin Guilliams; Freya R Svedberg
Journal:  Nat Immunol       Date:  2021-01-18       Impact factor: 25.606

4.  Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge.

Authors:  Candice Clay; Nathan Donart; Ndingsa Fomukong; Jennifer B Knight; Wanli Lei; Lance Price; Fletcher Hahn; Jesse Van Westrienen; Kevin S Harrod
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Lactobacillus priming of the respiratory tract: Heterologous immunity and protection against lethal pneumovirus infection.

Authors:  Katia E Garcia-Crespo; Calvin C Chan; Stanislaw J Gabryszewski; Caroline M Percopo; Peter Rigaux; Kimberly D Dyer; Joseph B Domachowske; Helene F Rosenberg
Journal:  Antiviral Res       Date:  2012-12-26       Impact factor: 5.970

Review 6.  Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries.

Authors:  Julia Henry; Richard J Smeyne; Haeman Jang; Bayard Miller; Michael S Okun
Journal:  Parkinsonism Relat Disord       Date:  2010-07-21       Impact factor: 4.891

7.  Clinical characteristics of infections caused by Mycoplasma pneumoniae P1 genotypes in children.

Authors:  Jasna Rodman Berlot; Uroš Krivec; Marina Praprotnik; Tatjana Mrvič; Rok Kogoj; Darja Keše
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-30       Impact factor: 3.267

8.  Detection of a TLR2 agonist by hematopoietic stem and progenitor cells impacts the function of the macrophages they produce.

Authors:  Alberto Yáñez; Nargess Hassanzadeh-Kiabi; Madelena Y Ng; Javier Megías; Aparna Subramanian; George Y Liu; David M Underhill; M Luisa Gil; Helen S Goodridge
Journal:  Eur J Immunol       Date:  2013-06-07       Impact factor: 5.532

9.  Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice.

Authors:  Sarah De Baets; Bert Schepens; Koen Sedeyn; Michael Schotsaert; Kenny Roose; Pieter Bogaert; Walter Fiers; Xavier Saelens
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

10.  CD11c⁺ cells primed with unrelated antigens facilitate an accelerated immune response to influenza virus in mice.

Authors:  Laura E Richert; Agnieszka Rynda-Apple; Ann L Harmsen; Soo Han; James A Wiley; Trevor Douglas; Kyle Larson; Rachelle V Morton; Allen G Harmsen
Journal:  Eur J Immunol       Date:  2014-01-13       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.